The Two-Mechanism Approach
CJC-1295 acts on GHRH receptors to increase the amplitude of GH pulses. Ipamorelin acts on GHSR receptors to increase the frequency of GH pulses. Together they provide additive stimulation through non-overlapping mechanisms — which is the scientific rationale for pairing them rather than using either alone.
Ipamorelin’s Selectivity Advantage
Ipamorelin was developed specifically for its selectivity. Unlike earlier GHRPs, it produces minimal cortisol or prolactin stimulation in animal studies. This selectivity is why physicians typically prefer Ipamorelin over less selective alternatives when designing GH optimization protocols.
Typical Protocol Structure
This combination is typically administered by subcutaneous injection 2-3 times daily, with at least one dose at bedtime. Protocol duration is typically 3-6 months with IGF-1 monitoring. A physician designs the specific dose based on your clinical picture and adjusts based on lab response.
Who Is This Protocol For
Physicians typically consider this protocol for patients with documented age-related GH decline interested in body composition, recovery, or energy optimization. It is not appropriate for everyone and requires proper clinical evaluation before prescription.